Risk Evaluation and Education for Alzheimer's Disease (REVEAL) IV
- Active, not recruiting
This study will examine the impact of receiving a genetic risk assessment for Alzheimer's disease among individuals with mild cognitive impairment (MCI).
|Minimum Age||Maximum Age||Gender||Healthy Volunteers|
|55 Years||90 Years||Both||No|
++Amnestic mild cognitive impairment (as defined by the Petersen criteria)++Fluent in English++Close friend, relative, or spouse willing to attend each study visit with the participant and complete surveys and interviews
++Current untreated anxiety or depression++Diagnosis of dementia or Alzheimer's disease
Apolipoprotein E (APOE) is a gene that can provide information about a person's chances of developing Alzheimer's disease. Some people with a diagnosis of MCI are curious to learn more about their chance of developing Alzheimer's. We will examine the psychological and behavioral impact of learning genetic information pertaining to the risk of progressing from MCI to Alzheimer's within 3 years.
This study requires participation in an education session, knowledge and attitudinal surveys, and tests to assess memory and thinking skills. Participants with MCI will have their blood drawn for genetic testing and be randomized to one of two groups. Those in the intervention arm will receive a 3-year risk estimate for the chance of progressing to dementia of the Alzheimer's type with the APOE gene test result. Those in the comparison arm will receive a 3-year risk estimate for the chance of progressing to dementia of the Alzheimer's type without the APOE gene test result. The latter group will have the opportunity to learn their own APOE gene test result at the end of the study.
Participants and their study partners will be followed for 6 months following disclosure of results, with one additional clinic visit and one additional phone interview.
|Washington||District of Columbia||20060||
- National Human Genome Research Institute (NHGRI) - NIH
- University of Michigan - Other
- University of Pennsylvania - Other
- Howard University - Other
|Robert C. Green, MD, MPH||Principal Investigator||Brigham and Women's Hospital/Harvard Medical School|
|Leo B. Waterstonemail@example.com|
- Kopits IM, Chen C, Roberts JS, Uhlmann W, Green RC. Willingness to Pay for Genetic Testing for Alzheimer`s Disease: A Measure of Personal Utility. Genet Test Mol Biomarkers. 2011 Jul 12; [Epub ahead of print]
- Akinleye I, Roberts JS, Royal CD, Linnenbringer E, Obisesan TO, Fasaye GA, Green RC. Differences Between African American and White Research Volunteers in Their Attitudes, Beliefs and Knowledge Regarding Genetic Testing for Alzheimer`s Disease. J Genet Couns. 2011 Jun 9; [Epub ahead of print]
- Christensen KD, Roberts JS, Uhlmann WR, Green RC. Changes to perceptions of the pros and cons of genetic susceptibility testing after APOE genotyping for Alzheimer disease risk. Genet Med. 2011 May;13(5):409-14.
- Roberts JS, Karlawish JH, Uhlmann WR, Petersen RC, Green RC. Mild cognitive im